The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock
Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.
Medtronic Stock Finds Its Footing—Now It's Gaining Momentum
The critical details are that price action cleared a crucial hurdle in early 2025, formed a Golden Crossover, and confirmed a completed market reversal following the fiscal year 2026 (F2026) Q2 earnings release.
S&P 500 Gains and Losses Today: Home Depot Slumps as Earnings Disappoint; Medtronic Stock Jumps
Shares of a major home improvement retailer lost ground after it missed quarterly profit forecasts, indicating homeowners are putting off remodeling projects amid economic uncertainty. Meanwhile, strong demand and procedure volumes helped drive a strong earnings report for a medical device company, and its shares advanced.
Medtronic plc (MDT) Q2 2026 Earnings Call Transcript
Medtronic plc ( MDT ) Q2 2026 Earnings Call November 18, 2025 8:00 AM EST Company Participants Ryan Weispfenning - VP & Head of Investor Relations Geoffrey Martha - Chairman of the Board & CEO Thierry Pieton - Executive VP & CFO Laura Mauri - Senior VP and Chief Scientific & Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Travis Steed - BofA Securities, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Pito Chickering - Deutsche Bank AG, Research Division Presentation Ryan Weispfenning VP & Head of Investor Relations Hello, everyone, and thanks for joining us today for our fiscal '26 second quarter video earnings webcast. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations.
Medtronic's Q2 Earnings & Revenues Beat Estimates, Stock Climbs
MDT posts Q2 earnings and revenue beat, powered by strong Cardiovascular growth and a raised 2026 outlook that lifts its shares.
Medtronic (MDT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medtronic (MDT) Q2 Earnings and Revenues Top Estimates
Medtronic (MDT) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.26 per share a year ago.
Medtronic Lifts Outlook as Quarterly Profit, Sales Rise
Medtronic raised its fiscal-year outlook after logging higher profit and sales in its latest quarter, boosted by robust demand across end markets and healthy procedure volumes.
Medtronic beats second-quarter estimates on strength in heart devices segment
Medical device maker Medtronic topped Wall Street estimates for second-quarter profit and revenue on Tuesday, driven by strong demand for its heart disease and diabetes devices.
Stay Ahead of the Game With Medtronic (MDT) Q2 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2025.
MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth
Medtronic's Q2 results may see a lift from solid Cardiovascular momentum and strong Diabetes segment growth.
Medtronic: Possible Earnings Beat Incoming But Still Overvalued
Medtronic plc offers stable dividends and consistent cash flow, but growth remains lackluster with revenues plateauing and limited expansion prospects. MDT's product pipeline, especially in cardiovascular health and diabetes, shows promise but is unlikely to significantly accelerate overall revenue or EPS growth. Shares are not attractively valued for growth investors, with a low risk profile but only modest returns; a 30% price drop would improve risk-reward.
